Tikva Allocell raises $8.0M Series A (United States, Jul 2026)
$8.0M
$8 Million Series AGenerated social card
Headline
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors - Macau Business
About
Tikva Allocell is focused on developing engineered EBV-specific T-cell therapies aimed at treating solid tumors. The company is advancing innovative treatments that leverage the immune system to target cancer cells more effectively.
Article summary
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors Macau Business
Investors
Related rounds
| Jul 25, 2026 | Braiding Robot | $7.0M | — | United States |
| Jul 25, 2026 | Casana | $46.0M | Series B | United States |
| Jul 24, 2026 | World Foundation | $52.5M | — | United States |
| Jul 24, 2026 | Petra Labs | $5.2M | — | United States |